https://scholars.lib.ntu.edu.tw/handle/123456789/145501
標題: | Management of Bacillus Calmette-Guerin osteomyelitis/osteitis in immunocompetent children-A systematic review | 作者: | Lin, Wen-Li Chiu, Nan-Chang Lee, Pin-Hui Huang, Angela Song-En Huang, Fu-Yuan Chi, Hsin Huang, Daniel Tsung-Ning Chan, Pei-Chun |
關鍵字: | BCG vaccine;Osteomyelitis;Osteitis;Disease management;Review | 公開日期: | 2015 | 卷: | 33 | 期: | 36 | 起(迄)頁: | 4391-4397 | 來源出版物: | Vaccine | 摘要: | Background: Bacillus Calmette-Guerin (BCG) osteomyelitis/osteitis in immunocompetent children is a rare but serious complication of BCG immunization. Rationale for its treatment is unclear. ;Methods: Due to the rarity of this complication, no randomized control trials has ever been conducted to evaluate methods of intervention. As such, we searched the literature for any reported BCG vaccination-related osteomyelitis/osteitis among immunecompetent children published before April 15, 2014. We summarized the data from different affected regions of the body by recording the number of reported cases, while noting outcomes and their medical and/or surgical interventions. ;Results: From 34 eligible studies gleaned from a screening of 804 articles, a total of 331 cases were enrolled. Involvement of the lower limbs was present in 55.6%, followed by the axial skeleton (26.0%), the upper limbs (15.4%), and multiple bones (3.0%). Of the 64 patients having records of detailed chemotherapy regimens, 45 patients (70%) received two or fewer drugs. Among the 80 patients with detailed surgical records, 50 (62.5%) received surgical procedures for diagnostic purposes. While there were uneventful outcomes for those receiving diagnostic procedures, 7 of the 30(23.3%) patients receiving surgical interventions had major complications (p= 0.002, Fisher's exact test). The overall prognosis was good with a 97.6% cure rate. Nevertheless, eight patients (2.4%) suffered major complications. ;Conclusions: The rationale for treatment of BCG osteomyelitis/osteitis in immunocompetent children is highly subjective. However, patients receiving diagnostic procedures instead of surgical interventions may avoid major complications. Because only a few of the publications had detailed treatment information, further studies are needed to identify proper treatments, while infant BCG vaccination is still in use. (C) 2015 Elsevier Ltd. All rights reserved. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/279721 | DOI: | 10.1016/j.vaccine.2015.07.039 | SDG/關鍵字: | BCG vaccine; ethambutol; isoniazid plus rifampicin; pyrazinamide; streptomycin; BCG vaccine; tuberculostatic agent; antimicrobial therapy; arm; BCG vaccination; bone biopsy; child; fine needle aspiration biopsy; histopathology; human; immunocompetence; leg; limb deformity; mortality; mycobacteriosis; onset age; orthopedic surgery; osteitis; osteomyelitis; outcome assessment; paralysis; pediatric surgery; polymerase chain reaction; postoperative complication; priority journal; prognosis; range of motion; Review; scoliosis; skeleton; systematic review; vaccination reaction; weakness; adolescent; chemically induced; debridement; infant; newborn; osteomyelitis; preschool child; Adolescent; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Debridement; Humans; Infant; Infant, Newborn; Osteomyelitis |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。